Predicting Recurrence of Non-Muscle-Invasive Bladder Cancer: Current Techniques and Future Trends

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Oct 27

PMID 36291803

Authors

Aya T Shalata

Mohamed Shehata

Eric van Bogaert

Khadiga M Ali

Ahmed Alksas

Ali Mahmoud

Eman M El-Gendy

Mohamed A Mohamed

Guruprasad A Giridharan

Sohail Contractor

Ayman El-Baz

Affiliations

Soon will be listed here.

Abstract

Bladder cancer (BC) is the 10th most common cancer globally and has a high mortality rate if not detected early and treated promptly. Non-muscle-invasive BC (NMIBC) is a subclassification of BC associated with high rates of recurrence and progression. Current tools for predicting recurrence and progression on NMIBC use scoring systems based on clinical and histopathological markers. These exclude other potentially useful biomarkers which could provide a more accurate personalized risk assessment. Future trends are likely to use artificial intelligence (AI) to enhance the prediction of recurrence in patients with NMIBC and decrease the use of standard clinical protocols such as cystoscopy and cytology. Here, we provide a comprehensive survey of the most recent studies from the last decade (N = 70 studies), focused on the prediction of patient outcomes in NMIBC, particularly recurrence, using biomarkers such as radiomics, histopathology, clinical, and genomics. The value of individual and combined biomarkers is discussed in detail with the goal of identifying future trends that will lead to the personalized management of NMIBC.

Citing Articles

A novel nomogram for predicting post-operative recurrence for patients with intermediate and high-risk non-muscle invasive bladder cancer after thulium laser resection of bladder tumors or conventional transurethral resection of bladder tumors....

Xu M, Sun J, Xiang Y, Hua Z, Liu C, An Y Transl Androl Urol. 2025; 14(1):91-102.

PMID: 39974795 PMC: 11833529. DOI: 10.21037/tau-24-535.

Evaluation of six novel biomarkers for predicting recurrence of non-muscle invasive bladder cancer after endoscopic resection- a prospective observational study.

Bardowska K, Krajewski W, Kolodziej A, Koscielska-Kasprzak K, Bartoszek D, Zabinska M World J Urol. 2025; 43(1):114.

PMID: 39928162 PMC: 11811479. DOI: 10.1007/s00345-025-05485-9.

Large-scale validation study of an improved semiautonomous urine cytology assessment tool: AutoParis-X.

Levy J, Chan N, Marotti J, Kerr D, Gutmann E, Glass R Cancer Cytopathol. 2023; 131(10):637-654.

PMID: 37377320 PMC: 11251731. DOI: 10.1002/cncy.22732.

Examining longitudinal markers of bladder cancer recurrence through a semiautonomous machine learning system for quantifying specimen atypia from urine cytology.

Levy J, Chan N, Marotti J, Rodrigues N, Ismail A, Kerr D Cancer Cytopathol. 2023; 131(9):561-573.

PMID: 37358142 PMC: 10527805. DOI: 10.1002/cncy.22725.

Artificial intelligence-driven radiomics study in cancer: the role of feature engineering and modeling.

Zhang Y, Zhang X, Cheng Y, Li B, Teng X, Zhang J Mil Med Res. 2023; 10(1):22.

PMID: 37189155 PMC: 10186733. DOI: 10.1186/s40779-023-00458-8.

References

Albayrak S, Zengin K, Tanik S, Atar M, Unal S, Imamoglu M . Can the neutrophil-to-lymphocyte ratio be used to predict recurrence and progression of non-muscle-invasive bladder cancer?. Kaohsiung J Med Sci. 2016; 32(6):327-33. DOI: 10.1016/j.kjms.2016.05.001. View

Ali-El-Dein B, Sooriakumaran P, Trinh Q, Barakat T, Nabeeh A, Ibrahiem E . Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre. BJU Int. 2013; 111(8):E331-41. DOI: 10.1111/bju.12026. View

Shkolyar E, Jia X, Chang T, Trivedi D, Mach K, Meng M . Augmented Bladder Tumor Detection Using Deep Learning. Eur Urol. 2019; 76(6):714-718. PMC: 6889816. DOI: 10.1016/j.eururo.2019.08.032. View

El-Assmy A, Abou-El-Ghar M, Refaie H, Mosbah A, El-Diasty T . Diffusion-weighted magnetic resonance imaging in follow-up of superficial urinary bladder carcinoma after transurethral resection: initial experience. BJU Int. 2012; 110(11 Pt B):E622-7. DOI: 10.1111/j.1464-410X.2012.11345.x. View

Maldonado L, Brait M, Michailidi C, Munari E, Driscoll T, Schultz L . An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine. Oncotarget. 2014; 5(14):5218-33. PMC: 4170626. DOI: 10.18632/oncotarget.2129. View

Zhang G, Xu L, Zhao L, Mao L, Li X, Jin Z . CT-based radiomics to predict the pathological grade of bladder cancer. Eur Radiol. 2020; 30(12):6749-6756. DOI: 10.1007/s00330-020-06893-8. View

Bi J, Liu H, Dong W, Xie W, He Q, Cai Z . Circular RNA circ-ZKSCAN1 inhibits bladder cancer progression through miR-1178-3p/p21 axis and acts as a prognostic factor of recurrence. Mol Cancer. 2019; 18(1):133. PMC: 6721182. DOI: 10.1186/s12943-019-1060-9. View

Chamie K, Litwin M, Bassett J, Daskivich T, Lai J, Hanley J . Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013; 119(17):3219-27. PMC: 3773281. DOI: 10.1002/cncr.28147. View

Botteman M, Pashos C, Redaelli A, Laskin B, Hauser R . The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2004; 21(18):1315-30. DOI: 10.1007/BF03262330. View

10.

Yin P, Kc K, Wei S, Yu Q, Li R, Haake A . Histopathological distinction of non-invasive and invasive bladder cancers using machine learning approaches. BMC Med Inform Decis Mak. 2020; 20(1):162. PMC: 7367328. DOI: 10.1186/s12911-020-01185-z. View

11.

Chen S, Jiang L, Zheng X, Shao J, Wang T, Zhang E . Clinical use of machine learning-based pathomics signature for diagnosis and survival prediction of bladder cancer. Cancer Sci. 2021; 112(7):2905-2914. PMC: 8253293. DOI: 10.1111/cas.14927. View

12.

Alongi P, Caobelli F, Gentile R, Stefano A, Russo G, Albano D . Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2016; 44(2):224-233. DOI: 10.1007/s00259-016-3500-8. View

13.

Tokuyama N, Saito A, Muraoka R, Matsubara S, Hashimoto T, Satake N . Prediction of non-muscle invasive bladder cancer recurrence using machine learning of quantitative nuclear features. Mod Pathol. 2021; 35(4):533-538. PMC: 8964412. DOI: 10.1038/s41379-021-00955-y. View

14.

Chevalier M, Trabanelli S, Racle J, Salome B, Cesson V, Gharbi D . ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest. 2017; 127(8):2916-2929. PMC: 5531411. DOI: 10.1172/JCI89717. View

15.

Witjes J, Morote J, Cornel E, Gakis G, P van Valenberg F, Lozano F . Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial. Eur Urol Oncol. 2019; 1(4):307-313. DOI: 10.1016/j.euo.2018.06.011. View

16.

Lee J, Choo M, Yoo S, Cho M, Son H, Jeong H . Intravesical Prostatic Protrusion and Prognosis of Non-Muscle Invasive Bladder Cancer: Analysis of Long-Term Data over 5 Years with Machine-Learning Algorithms. J Clin Med. 2021; 10(18). PMC: 8468209. DOI: 10.3390/jcm10184263. View

17.

Ferro M, Tataru O, Musi G, Lucarelli G, Abu Farhan A, Cantiello F . Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy. Diagnostics (Basel). 2022; 12(3). PMC: 8947693. DOI: 10.3390/diagnostics12030586. View

18.

Bartsch Jr G, Mitra A, Mitra S, Almal A, Steven K, Skinner D . Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder. J Urol. 2015; 195(2):493-8. DOI: 10.1016/j.juro.2015.09.090. View

19.

Roupret M, Gontero P, McCracken S, Dudderidge T, Stockley J, Kennedy A . Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study. J Urol. 2020; 204(4):685-690. DOI: 10.1097/JU.0000000000001084. View

20.

Su H, Jiang H, Tao T, Kang X, Zhang X, Kang D . Hope and challenge: Precision medicine in bladder cancer. Cancer Med. 2019; 8(4):1806-1816. PMC: 6488142. DOI: 10.1002/cam4.1979. View